A descriptive analysis of real-world treatment patterns of innovator (Remicade) and biosimilar infliximab in an infliximab-naïve Turkish population

about

A descriptive analysis of real-world treatment patterns of innovator (Remicade) and biosimilar infliximab in an infliximab-naïve Turkish population

Item

http://www.wikidata.org/entity/Q57484897

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

A descriptive analysis of real ...... ximab-naïve Turkish population

@en

A descriptive analysis of real-world treatment patterns of innovator

@nl

type

Item

label

A descriptive analysis of real ...... ximab-naïve Turkish population

@en

A descriptive analysis of real-world treatment patterns of innovator

@nl

prefLabel

A descriptive analysis of real ...... ximab-naïve Turkish population

@en

A descriptive analysis of real-world treatment patterns of innovator

@nl

P1476

A descriptive analysis of real ...... ximab-naïve Turkish population

@en

P2093

Adesuwa Ogbomo

http://www.w3.org/2001/XMLSchema#string

Amanda Teeple

http://www.w3.org/2001/XMLSchema#string

Ece A Mutlu

http://www.w3.org/2001/XMLSchema#string

Ismail Simsek

http://www.w3.org/2001/XMLSchema#string

Kavitha Goyal

http://www.w3.org/2001/XMLSchema#string

Lin Xie

http://www.w3.org/2001/XMLSchema#string

Lorie A Ellis

http://www.w3.org/2001/XMLSchema#string

Yusuf Yazici

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Infliximab for psoriasis.

The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

Infliximab: in ankylosing spondylitis.

Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey.

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.

P304

97-106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.S172241

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30323555

http://www.w3.org/2001/XMLSchema#string

P921

gastroenterology

Infections

P932

6174299

http://www.w3.org/2001/XMLSchema#string